SCHEMBL1015307

SCHEMBL1015307

O=C(COCC(=O)Nc1ccc(Cl)cc1C(=O)O)Nc1cccc(C2CCCCC2)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 7/20 0.64
POLB P06746 1/20 0.48
G6PD P11413 1/20 0.48
EPHX2 P34913 1/20 0.46
KDM4E B2RXH2 3/20 0.43
GAA P10253 1/20 0.43
HSD17B10 Q99714 2/20 0.43
KCNJ6 P48051 1/20 0.42
KCNJ3 P48549 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 2/20 0.41
KMO O15229 1/20 0.41
AKR1C4 P17516 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
AKR1C1 Q04828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014502 0.90 SERPINE1 (0.52) SERPINE1EPHX2KDM4EGAAKCNJ6
SCHEMBL1015276 0.89 SERPINE1 (0.65) SERPINE1POLBG6PDKDM4EGAA
SCHEMBL1012592 0.88 SERPINE1 (0.64) SERPINE1POLBG6PDKDM4EGAA
SCHEMBL418964 0.85 SERPINE1 (0.65) SERPINE1POLBG6PDKDM4EKCNJ6
SCHEMBL1015522 0.80 RAB9A (0.55) SERPINE1POLBG6PDEPHX2KDM4E
SCHEMBL419999 0.80 SERPINE1 (0.66) SERPINE1POLBG6PDGAAKCNJ6
SCHEMBL1013722 0.79 SERPINE1 (0.52) SERPINE1KDM4EHSD17B10KCNJ6KCNJ3
SCHEMBL1012593 0.79 SERPINE1 (0.52) SERPINE1KCNJ6KCNJ3ALDH1A1
SCHEMBL1797569 0.78 SERPINE1 (0.56) SERPINE1POLBG6PDKDM4EGAA
SCHEMBL419189 0.78 SERPINE1 (1.00) SERPINE1KMOAKR1C4AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SERPINE1 1/4885POLB 2992/4885G6PD 493/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885POLB 2824/4885G6PD 387/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885POLB 2556/4885G6PD 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.